Format

Send to

Choose Destination
Clin Chest Med. 2007 Mar;28(1):127-42; ix.

Prostanoid therapy for pulmonary arterial hypertension.

Author information

1
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Sciences University, Mail Code UHN67, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

Abstract

Epoprostenol and the structurally related compounds treprostinil, iloprost, and beraprost are collectively referred to as prostanoids. The discovery of epoprostenol in 1976 and unequivocal demonstration of its efficacy in 1996 dramatically altered the approach to therapy for pulmonary arterial hypertension (PAH). Development of prostanoids available through multiple routes of administration and the discovery and development of other agents acting through alternative pathways continue to expand the array of therapeutic options. The use of prostanoids in combination with other PAH drugs and for treating pulmonary hypertensive disorders outside of the PAH classification are areas of ongoing research.

PMID:
17338932
DOI:
10.1016/j.ccm.2006.11.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center